Effects of Integrative Medicine on Infectious Respiratory Diseases Including COVID-19

Covid19 Clinical Trial

— AtemNHK  

Official title:

Effects of Interventions and Lifestyle Modifications in Integrative Medicine and the Course of Infectious Respiratory Diseases Including COVID-19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04653727
• Other study ID #: AtemNHK
• Status: Completed
• Start date: January 6, 2021
• Est. completion date: March 5, 2021

Study information

• Verified date: September 2022
• Source: Charite University, Berlin, Germany
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The outbreak of the novel coronavirus SARS-CoV-2 caused a health emergency of international proportions when it was declared by the World Health Organization (WHO) in January 2020. Since then, the virus has spread internationally and the WHO has classified the outbreak as a pandemic. In the context of the increasing reporting of this pandemic and the increasing governmental measures to limit or slow down the spread of SARS-CoV-2 by all means, there is so far little scientific evidence for the effects of a healthy lifestyle on the disease. The aim of this study is to compare the potential of different, possibly protective lifestyles using the example of the COVID-19 pandemic. We will conduct an online survey with 3.000 participants using mobile website technology.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1287
• Est. completion date: March 5, 2021
• Est. primary completion date: March 5, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Present declaration of consent

Exclusion Criteria:

• Lack of consent to participate in the study

Related Conditions & MeSH terms

• COVID-19
• Covid19
• Influenza A
• Respiration Disorders
• Respiratory Disease
• Respiratory Tract Diseases

Intervention

Other:
• Cross-sectional survey
No intervention.

Locations

Country	Name	City	State
Germany	Charite University	Berlin

Sponsors (1)

Lead Sponsor	Collaborator
Charite University, Berlin, Germany

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Qualitative interviews		Conducted 1 month after completion of the questionnaire (once)
Primary	SARS-CoV-2 infection		Assessed retrospectively (last 6 months) with self-designed question
Secondary	Influenza virus infection		Assessed retrospectively (last 6 months) with self-designed question
Secondary	Other respiratory infections		Assessed retrospectively (last 6 months) with self-designed question
Secondary	Dietary habits		Assessed retrospectively (last 6 months) with self-designed question
Secondary	Sports activity		Assessed retrospectively (last 6 months) with self-designed question
Secondary	Time spent in nature		Assessed retrospectively (last 6 months) with self-designed question
Secondary	Use of hydrotherapy/Kneipp applications		Assessed retrospectively (last 6 months) with self-designed question
Secondary	Use of anthroposophic medicine		Assessed retrospectively (last 6 months) with self-designed question
Secondary	Use of digital health services		Assessed retrospectively (last 6 months) with self-designed question
Secondary	Use of phytotherapy		Assessed retrospectively (last 6 months) with self-designed question
Secondary	Use of dietary supplements		Assessed retrospectively (last 6 months) with self-designed question
Secondary	WHO-5 Well-Being Index	The scale ranges from 0 to 100, where 0 is the lowest level of well-being / lowest quality of life and 100 is the highest level of well-being / highest quality of life.	Assessed when filling out the questionnaire (Baseline)
Secondary	Numeric analog scale (NAS) stress	The NAS ranges from 0 to 10, where 0 is the lowest level of stress and 10 is the highest level of stress.	Assessed retrospectively (last 6 months) with self-designed question
Secondary	Numeric analog scale (NAS) anxiety	The NAS ranges from 0 to 10, where 0 is the lowest level of anxiety and 10 is the highest level of anxiety.	Assessed retrospectively (last 6 months) with self-designed question
Secondary	Numeric analog scale (NAS) depression	The NAS ranges from 0 to 10, where 0 is the lowest level of anxiety and 10 is the highest level of anxiety.	Assessed retrospectively (last 6 months) with self-designed question
Secondary	Use of relaxation / mind body approaches		Assessed retrospectively (last 6 months) with self-designed question
Secondary	Alcohol consumption		Assessed retrospectively (last 6 months) with self-designed question
Secondary	Cigarette consumption		Assessed retrospectively (last 6 months) with self-designed question
Secondary	Self-efficacy	The scale ranges from 0 to 100, where 0 is the lowest level of self-efficacy and 100 is the highest level of self-efficacy.	Assessed when filling out the questionnaire (Baseline)
Secondary	Sick leave		Assessed retrospectively (last 6 months) with self-designed question